Endothelial progenitor cells as therapeutic agents in the microcirculation: An update

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 9-22

  Napoli, Claudio ^a,b   Hayashi, Toshio ^c   Cacciatore, Francesco ^d   Casamassimi, Amelia ^a   Casini, Costanza ^a,e   Al Omran, Mohammed ^b   Ignarro, Louis J ^b,f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Endothelial progenitor cells; Preclinical studies; Vascular repair

Indexed keywords

ATORVASTATIN; CD133 ANTIGEN; CD14 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CELL MARKER; CHEMOKINE RECEPTOR CXCR4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ANEMIA; ANGIOGENESIS; ANTIGENICITY; BONE MARROW; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL HOMING; CELL HYPOXIA; CELL INTERACTION; CELL MIGRATION; CELL THERAPY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HEART FAILURE; HEMANGIOBLAST; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC HEART DISEASE; MICROCIRCULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGENERATIVE MEDICINE; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEM CELL MOBILIZATION; STROKE; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL CELLS; HUMANS; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 79952103374     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.039     Document Type: Review

References (174)

1. Napoli C., Cacciatore F. Novel pathogenic insights in the primary prevention of cardiovascular disease. Progress in Cardiovascular Diseases 2009, 51:503-523.
2. Ferkowicz M.J., Yoder M.C. Blood island formation: longstanding observations and modern interpretations. Experimental Haematology 2005, 33:1041-1047.
3. McGrath K.E., Palis J. Hematopoiesis in the yolk sac: more than meets the eye. Experimental Hematology 2005, 33:1021-1028.
4. Eilken H.M., Nishikawa S., Schroeder T. Continuous single-cell imaging of blood generation from haemogenic endothelium. Nature 2009, 457:896-900.
5. Lancrin C., Sroczynska P., Stephenson C., Allen T., Kouskoff V., Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 2009, 457:892-895.
6. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
7. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
8. Gehling U.M., Ergün S., Schumacher U., Wagener C., Pantel K., Otte M., et al. In vitro differentiation of endothelial cells from AC 133 positive progenitor cells. Blood 2000, 95:3106-3112.
9. Lu S.J., Feng Q., Caballero S., Chen Y., Moore M., Grant M., et al. Generation of functional hemangioblasts from human embryonic stem cells. Nature Methods 2007, 4:501-509.
10. Yoder M.C., Mead L.E., Prater D., Krier T.R., Mroueh K.N., Li F., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
11. Timmermans F., Van Hauwermeiren F., De Smedt M., Raedt R., Plasschaert F., De Buyzere M.L., et al. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arteriosclerosis, Thrombosis and Vascular Biology 2007, 27:1572-1579.
12. Pearson J.D. Endothelial progenitor cells-an evolving story. Microvascular Reseasrch 2010, 79:162-168.
13. Casamassimi A., Balestrieri M.L., Fiorito C., Schiano C., Maione C., Rossiello R., et al. Comparison between total endothelial progenitor cell isolation versus enriched CD133+ culture. Journal of Biochemistry 2007, 141:503-511.
14. Zampetaki A., Kirton J.P., Xu Q. Vascular repair by endothelial progenitor cells. Cardiovascular Research 2008, 78:413-421.
15. Yanai S., Adachi Y., Shi M., Shigematsu A., Shima C., Imai Y., et al. Adult bone marrow cells can differentiate into hemopoietic cells and endothelial cells but not into other lineage cells in normal growth and normal life. International Journal of Hematology 2010, 91:213-218.
16. Moonen J.R., Krenning G., Brinker M.G., Koerts J.A., van Luyn M.J., Harmsen M.C. Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny. Cardiovascular Research 2010, 6:506-515.
17. Vajkoczy P., Blum S., Lamparter M., Mailhammer R., Erber R., Engelhardt B., et al. Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. The Journal of Experimental Medicine 2003, 197:1755-1765.
18. Cherqui S., Kurian S.M., Schussler O., Hewel J.A., Yates J.R., Salomon D.R. Isolation and angiogenesis by endothelial progenitors in the fetal liver. Stem Cell 2006, 24:44-54.
19. Voyta J.C., Via D.P., Butterfield C.E., Zetter B.R. Identification and isolation of endothelial cells based on their increased uptake of acetylated-low density lipoprotein. Journal of Cell Biology 1984, 99:2034-2040.
20. Napoli C., Maione C., Schiano C., Fiorito C., Ignarro L.J. Bone marrow cell-mediated cardiovascular repair: potential of combined therapies. Trends in Molecular Medicine 2007, 13:278-286.
21. Burt R.K., Loh Y., Pearce W., Beohar N., Barr W.G., Craig R., et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008, 299:925-936.
22. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscleriosclerosis, Thrombosis, and Vascular Biology 2003, 23:168-175.
23. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288:373-376.
24. Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678.
25. Ignarro L.J., Cirino G., Casini A., Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. Journal of Cardiovascular Pharmacology 1999, 34:879-886.
26. Crimi E., Ignarro L.J., Napoli C. Microcirculation and oxidative stress. Free Radical Research 2007, 41:1364-1375.
27. Ross R. Atherosclerosis-an inflammatory disease. The New England Journal of Medicine 1999, 340:115-126.
28. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nature Medicine 2002, 8:1249-1256.
29. Werner N., Nickenig G. Clinical and therapeutical implications of EPC biology in atherosclerosis. Journal of Cellular and Molecular Medicine 2006, 10:318-332.
30. Karra R., Vemullapalli S., Dong C., Herderick E.E., Song X., Slosek K., et al. Molecular evidence for arterial repair in atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:16789-16794.
31. Werner N., Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?. Arteriosclerosis, Thrombosis and Vascular Biology 2006, 26:257-266.
32. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochemical Pharmacology 2001, 61:253-270.
33. Dimmeler S., Zeiher A.M. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis. Journal of Molecular Medicine 2004, 82:671-677.
34. Dzau V.J., Gnecchi M., Pachori A.S., Morello F., Melo L.G. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension 2005, 46:7-18.
35. Dotsenko O. Stem/Progenitor cells, atherosclerosis and cardiovascular regeneration. The Open Cardiovascular Medicine Journal 2010, 4:97-104.
36. Metharom P., Caplice N.M. Vascular disease: a new progenitor biology. Current Vascular Pharmacology 2007, 5:61-68.
37. Jia L., Takahashi M., Yoshioka T., Morimoto H., Ise H., Ikeda U. Therapeutic potential of endothelial progenitor cells for cardiovascular diseases. Current Vascular Pharmacology 2006, 4:59-65.
38. Newman R.E., Yoo D., LeRoux M.A., Danilkovitch-Miagkova A. Treatment of inflammatory diseases with mesenchymal stem cells. Inflammation and Allergy Drug Targets 2009, 8:110-123.
39. Vasa M., Fichtlscherer S., Aicher A., Adler K., Urbich C., Martin H., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circulation Research 2001, 89:E1-7.
40. Liguori A., Fiorito C., Balestrieri M.L., Crimi E., Bruzzese G., Williams-Ignarro S., et al. Functional impairment of hematopoietic progenitor cells in patients with coronary heart disease. European Journal of Hematology 2008, 80:258-264.
41. Kinnaird T., Stabile E., Zbinden S., Burnett M.S., Epstein S.E. Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions. Cardiovascular Research 2008, 78:257-264.
42. Spinetti G., Kraenkel N., Emanueli C., Madeddu P. Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovascular Research 2008, 78:265-273.
43. Feihl F., Liaudet L., Levy B.I., Waeber B. Hypertension and microvascular remodelling. Cardiovascular Research 2008, 78:274-285.
44. Lijnen H.R. Angiogenesis and obesity. Cardiovascular Research 2008, 78:286-293.
45. Balestrieri M.L., Rienzo M., Felice F., Rossiello R., Grimaldi V., Milone L., et al. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochimica and Biophysica Acta 2008, 1784:936-945.
46. Umemura T., Soga J., Hidaka T., Takemoto H., Nakamura S., Jitsuiki D., et al. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. American Journal of Hypertension 2008, 21:1203-1209.
47. Briguori C., Testa U., Riccioni R., Colombo A., Petrucci E., Condorelli G., et al. Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. The FASEB Journal 2010, 24:1981-1988.
48. Balestrieri M.L., Fiorito C., Crimi E., Felice F., Schiano C., Milone L., et al. Effect of red wine antioxidants and minor polyphenolic constituent on endothelial progenitor cells after physical training in mice. International Journal of Cardiology 2008, 126:295-297.
49. Balestrieri M.L., Schiano C., Felice F., Casamassimi A., Balestrieri A., Milone L., et al. Effect of low doses of red wine and pure resveratrol on circulating endothelial progenitor cells. Jounal of Biochemistry 2008, 143:179-186.
50. Baron-Menguy C., Bocquet A., Guihot A.L., Chappard D., Amiot M.J., Andriantsitohaina R., et al. Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses anti-angiogenic. FASEB Journal 2007, 21:3511-3521.
51. Fiorito C., Rienzo M., Crimi E., Rossiello R., Balestrieri M.L., Casamassimi A., et al. Antioxidants increase number of progenitor endothelial cells through multiple gene expression pathways. Free Radical Research 2008, 42:754-762.
52. Salvatore P., Casamassimi A., Sommese L., Fiorito C., Ciccodicola A., Rossiello R., et al. Detrimental effects of Bartonella henselae are counteracted by L-arginine and nitric oxide in human endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:9427-9432.
53. Kushner E.J., Van Guilder G.P., Maceneaney O.J., Cech J.N., Stauffer B.L., Desouza C.A. Aging and endothelial progenitor cell telomere length in healthy men. Arteriosclerosis, Thrombosis and Vascular Biology 2009, 29:121-127.
54. Gössl M., Mödder U.I., Atkinson E.J., Lerman A., Khosla S. Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. Journal of the American College of Cardiology 2008, 52:1314-1325.
55. Fadini G.P., Agostini C., Boscaro E., Avogaro A. Mechanisms and significance of progenitor cell reduction in the metabolic syndrome. Metabolic Syndrome Related Disorders 2009, 7:5-10.
56. Naik R.P., Jin D., Chuang E., Gold E.G., Tousimis E.A., Moore A.L., et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Research and Treatment 2008, 107:133-138.
57. Westerweel P.E., Verhaar M.C. Endothelial progenitor cell dysfunction in rheumatic disease. Nature Review in Rheumatology. 2009, 5:332-340.
58. Biguzzi E., Mancuso P., Franchi F., Calleri A., Mancuso M.E., Santagostino E., et al. Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. British Journal of Haematology 2009, 144:803-805.
59. Jie K.E., Zaikova M.A., Bergevoet M.W., Westerweel P.E., Rastmanesh M., Blankestijn P.J., et al. Progenitor cells and vascular function are impaired in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2010, 25:1875-1882.
60. Sala E., Villena C., Balaguer C., Ríos A., Fernández-Palomeque C., Cosío B.G., et al. Abnormal Levels of Circulating Endothelial Progenitor Cells During Exacerbations of COPD. Lung 2010, 188:331-338.
61. Rafii S., Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nature Medicine 2003, 9:702-712.
62. Hristov M., Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. Journal of Cellular and Molecular Medicine 2004, 8:498-508.
63. Shantsila E., Watson T., Tse H.F., Lip G.Y. New insights on endothelial progenitor cell subpopulations and their angiogenic properties. Journal of the American College of Cardiology 2008, 51:669-671.
64. Sieveking D.P., Buckle A., Celermajer D.S., Ng M.K. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. Journal of the American College of Cardiology 2008, 51:660-668.
65. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., et al. Ischemia- and cytokine-induced mobilization of bone-marrow-derived endothelial progenitor cells for neovascularization. Nature Medicine 1999, 5:434-438.
66. Kalka C., Masuda H., Takahashi T., Kalka-Moll W.M., Silver M., Kearney M., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:3422-3427.
67. Shintani S., Murohara T., Ikeda H., Ueno T., Honma T., Katoh A., et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001, 103:2776-2779.
68. Kong D., Melo L.G., Gnecchi M., Zhang L., Mostoslavsky G., Liew C.C., et al. Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation 2004, 110:2039-2046.
69. Fujiyama S., Amano K., Uehira K., Yoshida M., Nishiwaki Y., Nozawa Y., et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circulation Research 2003, 93:980-989.
70. Werner N., Junk S., Laufs U., Link A., Walenta K., Bohm M., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circulation Research 2003, 93:e17-e24.
71. Rohde E., Malischnik C., Thaler D., Maierhofer T., Linkesch W., Lanzer G., et al. Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006, 24:357-367.
72. Schatteman G.C., Hanlon H.D., Jiao G., Dodds S.G., Christy B.A. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. Journal of Clinical Investigations 2000, 106:571-578.
73. Kalka C., Masuda H., Takahashi T., Gordon R., Tepper O., Gravereaux E., et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circulation Research 2000, 86:1198-1202.
74. Kalka C., Tehrani H., Laudenberg B., Vale P.R., Isner J.M., Asahara T., et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. The Annals of Thoracic Surgery 2000, 70:829-834.
75. Gill M., Dias S., Hattori K., Rivera M.L., Hicklin D., Witte L., et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circulation Research 2001, 88:167-174.
76. Semenza G.L. Angiogenesis in ischemic and neoplastic disorders. Annual Review of Medicine 2003, 54:17-28.
77. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Medicine 2004, 10:858-864.
78. Galiano R.D., Tepper O.M., Pelo C.R., Bhatt K.A., Callaghan M., Bastidas N., et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow derived cells. The American Journal of Pathology 2004, 164:1935-1947.
79. Dobaczewski M., Bujak M., Zymek P., Ren G., Entman M.L., Frangogiannis N.G. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell and Tissue Research 2006, 324:475-488.
80. Young P.P., Vaughan D.E., Hatzopoulos A.K. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Progress in Cardiovascular Disease 2007, 49:421-429.
81. Li B., Sharpe E.E., Maupin A.B., Teleron A.A., Pyle A.L., Carmeliet P., et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB Journal 2006, 20:1495-1497.
82. de Nigris F., Balestrieri M.L., Williams-Ignarro S., D'Armiento F.P., Lerman L.O., Byrns R., et al. Therapeutic effect of autologous bone marrow cells and metabolic intervention in the ischemic hindlimb of spontaneously hypertensive rats involve reduced cell senescence and CXCR4/Akt/eNOS pathways. Journal of Cardiovascular Pharmacology 2007, 4:424-433.
83. Takamiya M., Okigaki M., Jin D., Takai S., Nozawa Y., Adachi Y., et al. Granulocyte colony-stimulating factor-mobilized circulating c-Kit+/Flk-l+ progenitor cells regenerate endothelium and inhibit neointimal hyperplasia after vascular injury. Arteriosclerosis, Thrombosis and Vascular Biology 2006, 26:751-757.
84. Napoli C., William-Ignarro S., Byrns R., Balestrieri M.L., Crimi E., Farzati B., et al. Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nature Clinical Practice Cardiovascular Medicine 2008, 5:571-579.
85. Körbling M., Reuben J.M., Gao H., Lee B.N., Harris D.M., Cogdell D., et al. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 2006, 46:1795-1802.
86. Anderlini P., Champlin R.E. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008, 111:1767-1772.
87. Hill J.M., Syed M.A., Arai A.E., Powell T.M., Paul J.D., Zalos G., et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. Journal of the American College of Cardiology 2005, 46:1643-1648.
88. Kang H.J., Kim H.S., Zhang S.Y., Park K.W., Cho H.J., Koo B.K., et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004, 363:751-756.
89. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood 2003, 102:1340-1346.
90. Bahlmann F.H., De Groot K., Spandau J.M., Landry A.L., Hertel B., Duckert T., et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004, 103:921-926.
91. Devin J.K., Young P.P. The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. Current Opinion in Investigational Drugs 2008, 9:983-992.
92. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
93. Aicher A., Heeschen C., Mildner-Rihm C., Urbich C., Ihling C., Technau-Ihling K., et al. Essential role of endothelial nitric oxide syntase for mobilization of stem and progenitor cells. Nature Medicine 2003, 9:1370-1376.
94. Maeng Y.S., Choi H.J., Kwon J.Y., Park Y.W., Choi K.S., Min J.K., et al. Endothelial progenitor cell homing: prominent role of the IGF2-IGF2R-PLC{beta}2 axis. Blood 2009, 113:233-243.
95. Di Bernardo G., Galderisi U., Fiorito C., Squillaro T., Cito L., Cipollaro M., et al. Dual role of parathyroid hormone in endothelial progenitor cells and marrow stromal mesenchymal stem cells. Journal of Cellular Physiology 2010, 222:474-480.
96. Pagliarulo C., Salvatore P., Napoli C. Targeting vascular niche by parathyroid hormone. Current Medicinal Chemistry 2008, 15:2984-2990.
97. Shantsila E., Watson T., Lip G.Y. Endothelial progenitor cells in cardiovascular disorders. Journal of the American College of Cardiology 2007, 49:741-752.
98. Carmeliet P., Baes M. Metabolism and therapeutic angiogenesis. The New England Journal of Medicine 2008, 358:2511-2512.
99. Eguchi M., Masuda H., Asahara T. Endothelial progenitor cells for postnatal vasculogenesis. Clinical and Experimental Nephrology 2007, 11:18-25.
100. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO Journal 1999, 18:3964-3972.
101. Isner J.M., Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. The Journal of Clinical Investigation 1999, 103:1231-1236.
102. Schatteman G.C., Dunnwald M., Jiao C. Biology of bone marrow-derived endothelial cell precursors. American Journal of Physiology Heart and Circulation Physiology 2007, 292:H1-18.
103. Zwaginga J.J., Doevendans P. Stem cell-derived angiogenic/vasculogenic cells: possible therapies for tissue repair and tissue engineering. Clinical and Experimental Pharmacology and Physiology 2003, 30:900-908.
104. Ben-Shoshan J., George J. Endothelial progenitor cells as therapeutic vectors in cardiovascular disorders: From experimental models to human trials. Pharmacology & Therapeutics 2007, 115:25-36.
105. Liew A., Barry F., O'Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. Bioessays 2006, 28:261-270.
106. Kunz G.A., Liang G., Cuculi F., Gregg D., Vata K.C., Shaw L.K., et al. Circulating endothelial progenitor cells predict coronary artery disease severity. American Heart Journal 2006, 152:190-195.
107. Napoli C., Farzati B., Sica V., Iannuzzi E., Coppola G., Silvestroni A., et al. Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia. European Journal of Cardiovascular Prevention and Rehabilitation 2008, 15:709-718.
108. Kawamoto A., Gwon H.C., Iwaguro H., Yamaguchi J.I., Uchida S., Masuda H., et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001, 103:634-637.
109. Urbich C., Heeschen C., Aicher A., Dernbach E., Zeiher A.M., Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003, 108:2511-2516.
110. Murohara T. Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors. Trends in Cardiovascular Medicine 2001, 11:303-307.
111. Walter D.H., Rittig K., Bahlmann F.H., Kirchmair R., Silver M., Murayama T., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105:3017-3024.
112. Strehlow K., Werner N., Berweiler J., Link A., Dirnagl U., Priller J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 2003, 107:3059-3065.
113. He T., Smith L.A., Harrington S., Nath K.A., Caplice N.M., Katusic Z.S. Transplantation of circulating endothelial progenitor cells restores endothelial function of denuded rabbit carotid arteries. Stroke 2004, 35:2378-2384.
114. Griese D.P., Ehsan A., Melo L.G., Kong D., Zhang L., Mann M.J., et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003, 108:2710-2715.
115. Kantor B., Ashai K., Holmes, Schwartz R.S. The experimental animal models for assessing treatments of restenosis. Cardiovascular Radiation Medicine 1999, 1:48-54.
116. Bennett M.R., O'Sullivan M.O. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacology & Therapeutics 2001, 91:149-166.
117. Leone A.M., Rutella S., Bonanno G., Abbate A., Rebuzzi A.G., Giovannini S., et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. European Heart Journal 2005, 26:1196-1204.
118. Xu Q., Zhang Z., Davison F., Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. Circulation Research 2003, 93:e76-e86.
119. Takahashi M., Nakamura T., Toba T., Kajiwara N., Kato H., Shimizu Y. Transplantation of EPC into the lung to alleviate pulmonary hypertension in dogs. Tissue Engineering 2004, 10:771-779.
120. Shi Q., Rafii S., Wu M.H., Wijelath E.S., Yu C., Ishida A., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998, 92:362-367.
121. Griese D.P., Achatz S., Batzlsperger C.A., Strauch U.G., Grumbeck B., Weil J., et al. Vascular gene delivery of anticoagulants by transplantation of retrovirally-transduced endothelial progenitor cells. Cardiovascular Research 2003, 58:469-477.
122. Iwaguro H., Yamaguchi J., Kalka C., Murasawa S., Masuda H., Hayashi S., et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002, 105:732-738.
123. Grant M.B., May W.S., Caballero S., Brown G.A., Guthrie S.M., Mames R.N., et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nature Medicine 2002, 8:607-612.
124. Kong D., Melo L.G., Mangi A.A., Zhang L., Lopez-Ilasaca M., Perrella M.A., et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004, 109:1769-1775.
125. Kaur S., Kumar T.R., Uruno A., Sugawara A., Jayakumar K., Kartha C.C. Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: an in vitro study. Basic Research in Cardiology 2009, 104:739-749.
126. Wegiel B., Gallo D.J., Raman K.G., Karlsson J.M., Ozanich B., Chin B.Y., et al. Nitric Oxide-Dependent Bone Marrow Progenitor Mobilization by Carbon Monoxide Enhances Endothelial Repair After Vascular Injury. Circulation 2010, 121:537-548.
127. Jiang M., Wang B., Wang C., He B., Fan H., Guo T.B., et al. Angiogenesis by transplantation of HIF-1 alpha modified EPCs into ischemic limbs. Journal of Cellular Biochemistry 2008, 103:321-334.
128. Jackson K.A., Majka S.M., Wang H., Pocius J., Hartley C.J., Majesky M.W., et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. The Journal of Clinical Investigation 2001, 107:1395-1402.
129. Yamaguchi J., Kusano K.F., Masuo O., Kawamoto A., Silver M., Murasawa S., et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003, 107:1322-1328.
130. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. The New England Journal of Medicine 2003, 348:593-600.
131. Ribatti D. The discovery of endothelial progenitor cells: an historical review. Leukemia Research 2007, 31:439-444.
132. Napoli C., Balestrieri A., Ignarro L.J. Therapeutic approaches in vascular repair induced by adult bone marrow cells and circulating progenitor endothelial cells. Current Pharmaceutical Design 2007, 13:3245-3251.
133. Wojakowski W., Tendera M., Michałowska A., Majka M., Kucia M., Maślankiewicz K., et al. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation 2004, 110:3213-3220.
134. Massa M., Rosti V., Ferrario M., Campanelli R., Ramajoli I., Rosso R., et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005, 105:199-206.
135. Salter A.B., Meadows S.K., Muramoto G.G., Himburg H., Doan P., Daher P., et al. Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo. Blood 2009, 113:2104-2107.
136. Werner N., Priller J., Laufs U., Endres M., Böhm M., Dirnagl U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arteriosclerosis, Thrombosis and Vascular Biology 2002, 22:1567-1572.
137. Leone A.M., Rutella S., Giannico M.B., Perfetti M., Zaccone V., Brugaletta S., et al. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. International Journal of Cardiology 2008, 130:457-462.
138. Vasa M., Fichtlscherer S., Adler K., Aicher A., Martin H., Zeiher A.M., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary arterial disease. Circulation 2001, 103:2885-2890.
139. Eizawa T., Ikeda U., Murakami Y., Matsui K., Yoshioka T., Takahashi M., et al. Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart 2004, 90:685-686.
140. Wang X., Chen J., Tao Q., Zhu J., Shang Y. Effects of ox-LDL on number and activity of circulating endothelial progenitor cells. Drug and Chemical Toxicology 2004, 27:243-255.
141. Smadja D.M., Cornet A., Emmerich J., Aiach M., Gaussem P. Endothelial progenitor cells: characterization, in vitro expansion, and prospect for autologous cell therapy. Cell Biology and Toxicology 2007, 23:223-239.
142. Simper D., Wang S., Deb A., Holmes D., McGregor C., Frantz R., et al. Endothelial progenitor cells are decreased in blood of cardiac allografts patients with vasculopathy and endothelial cells of non cardiac origin are enriched in transplant atherosclerosis. Circulation 2003, 108:143-149.
143. Ghani U., Shuaib A., Salam A., Nasir A., Shuaib U., Jeerakathil T., et al. Endothelial progenitor cells during cerebrovascular disease. Stroke 2005, 36:151-153.
144. Orlic D., Kajstura J., Chimenti S., Jakoniuk I., Anderson S.M., Li B., et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001, 410:701-705.
145. Fadini G.P., Boscaro E., de Kreutzenberg S., Agostini C., Seeger F., Dimmeler S., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes mellitus. Diabetes Care 2010, 33:1097-1102.
146. Assmus B., Schächinger V., Teupe C., Britten M., Lehmann R., Döbert N., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002, 106:3009-3017.
147. Schächinger V., Assmus B., Britten M.B., Honold J., Lehmann R., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. Journal of the American College of Cardiology 2004, 44:1690-1699.
148. Erbs S., Linke A., Adams V., Lenk K., Thiele H., Diederich K.W., et al. Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circulation Research 2005, 97:756-762.
149. Katritsis D.G., Sotiropoulou P.A., Karvouni E., Karabinos I., Korovesis S., Perez S.A., et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheterization and Cardiovascular Interventions 2005, 65:321-329.
150. Assmus B., Fischer-Rasokat U., Honold J., Seeger F.H., Fichtlscherer S., Tonn T., et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circulation Research 2007, 100:1234-1241.
151. Assmus B., Honold J., Schächinger V., Britten M.B., Fischer-Rasokat U., Lehmann R., et al. Transcoronary transplantation of progenitor cells after myocardial infarction. The New England Journal of Medicine 2006, 355:1222-1232.
152. Wang X.X., Zhang F.R., Shang Y.P., Zhu J.H., Xie X.D., Tao Q.M., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. Journal of the American College of Cardiology 2007, 49:1566-1571.
153. Huang P.H., Chen Y.H., Tsai H.Y., Chen J.S., Wu T.C., Lin F.Y., et al. Intake of red wine increases the number and functional capacity of circulating endothelial progenitor cells by enhancing nitric oxide bioavailability. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:869-877.
154. Mikirova N.A., Jackson J.A., Hunninghake R., Kenyon J., Chan K.W., Swindlehurst C.A., et al. Nutraceutical augmentation of circulating endothelial progenitor cells and hematopoietic stem cells in human subjects. J Translational Medicine 2010, 8:34.
155. Fadini G.P., Boscaro E., Albiero M., Menegazzo L., Frison V., de Kreutzenberg S., et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010, 33:1607-1609.
156. Lara-Hernandez R., Lozano-Vilardell P., Blanes P., Torreguitart-Mirada N., Galmés A., Besalduch J. Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Annals of Vascular Surgery 2010, 24:287-294.
157. Dimmeler S., Zeiher A.M. Cell therapy of Acute Myocardial Infarction: open questions. Cardiology 2009, 113:155-160.
158. Chong E., Poh K.K., Liang S., Lee R.C., Low A., Teo S.G., et al. Two-year clinical registry follow-up of endothelial progenitor cell capture stent versus sirolimus-eluting bioabsorbable polymer-coated stent versus bare metal stents in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction. The journal of Interventional Cardiology 2010, 23:101-108.
159. Bystroń M., Cervinka P., Spacek R., Kvašňák M., Jakabčin J., Cervinková M., et al. Randomized comparison of endothelial progenitor cells capture stent versus cobalt-chromium stent for treatment of st-elevation myocardial infarction six-month clinical, angiographic and IVUS follow-up. Catheterization and Cardiovascular Interventions 2010, 76:627-631.
160. Cesari F., Sofi F., Caporale R., Capalbo A., Marcucci R., Macchi C., et al. Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation. Thrombosis and Haemostasis 2009, 101:521-526.
161. Kawamoto A., Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheterization and Cardiovascular Interventions 2007, 70:477-484.
162. Pearson J.D. Endothelial progenitor cells-hype or hope?. Journal of Thrombosis and Haemostasis 2009, 7:255-262.
163. Dedobbeleer C., Blocklet D., Toungouz M., Lambermont M., Unger P., Degaute J.P., et al. Myocardial homing and coronary endothelial function after autologous blood cd34+ progenitor cells intracoronary injection in the chronic phase of myocardial infarction. Journal of Cardiovascular Pharmacology 2009, 53:480-485.
164. Ott H.C., Matthiesen T.S., Goh S.K., Black L.D., Kren S.M., Netoff T.I., et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nature Medicine 2008, 14:213-221.
165. Bondar B., Fuchs S., Motta A., Migliaresi C., Kirkpatrick C.J. Functionality of endothelial cells on silk fibroin nets: comparative study of micro- and nanometric fibre size. Biomaterials 2008, 29:561-572.
166. Wilhelm C., Bal L., Smirnov P., Galy-Fauroux I., Clément O., Gazeau F., et al. Magnetic control of vascular network formation with magnetically labeled endothelial progenitor cells. Biomaterials 2007, 28:3797-3806.
167. Schantz J.T., Chim H., Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Engineering 2007, 13:2615-2624.
168. Silva E.A., Kim E.S., Kong H.J., Mooney D.J. Material-based deployment enhances efficacy of endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14347-14352.
169. Yin T., Li L. The stem cell niches in bone. The Journal of Clinical Investigations 2006, 116:1195-1201.
170. Chung Y., Klimanskaya I., Becker S., Li T., Maserati M., Lu S.J., et al. Human embryonic stem cell lines generated without embryo destruction. Cell Stem Cell 2008, 2:113-117.
171. Tendera M., Wojakowski W., Ruzyłło W., Chojnowska L., Kepka C., Tracz W., et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. European Heart Journal 2009, 30:1313-1321.
172. Landmesser U. Bone marrow cell therapy after myocardial infarction. What should we select?. European Heart Journal 2009, 30:1310-1312.
173. Blum B., Benvenisty N. The tumorigenicity of human embryonic stem cells. Advances in Cancer Research 2008, 100:133-158.
174. Balestrieri M.L., Lu S.J., de Nigris F., Giovane A., Williams-Ignarro S., D'Armiento F.P., et al. Therapeutic angiogenesis in diabetic apolipoprotein E-deficient mice using bone marrow cells, functional hemangioblasts, and metabolic intervention. Atherosclerosis 2010, 209:403-414.